trending Market Intelligence /marketintelligence/en/news-insights/trending/been-nfk2dhadzamn7vrla2 content esgSubNav
In This List

Halozyme Therapeutics director to step down

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Halozyme Therapeutics director to step down

Randal Kirk informed Halozyme Therapeutics Inc. of his unavailability to serve as a director due to his growing commitments outside of the company.

Due to this development, Kirk will not be nominated for re-election to the board at the upcoming stockholders' annual meeting.

San Diego, Calif.-based Halozyme Therapeutics is a biotechnology company which researches, develops, and commercializes human enzymes and other drug candidates in the U.S., Switzerland, and internationally.